Holen Sie sich die Stockscreener-App
501.19
0.29%
1.43
Handel nachbörslich:
501.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
MDGL Maintained by B of A Securities -- Price Target Lowered to $542 - GuruFocus
BofA cuts Madrigal Pharmaceuticals price target on competition concerns By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals launches 'MASH Across America' with giant inflatable liver in Philly - PharmaLive
MDGL: Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained growth - TradingView
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event - MyChesCo
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential - DirectorsTalk Interviews
Goldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Fiera Capital Corp Acquires 41,656 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Return on invested capital % of Madrigal Pharmaceuticals, Inc. – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. News — XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1 - TradingView
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com
(MDGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Legal & General Group Plc Sells 6,440 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress - Insider Monkey
Madrigal Highlights Rezdiffra Data as MASH Market Expands - MyChesCo
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - The Manila Times
12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Geode Capital Management LLC Has $263.11 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals targets liver disease with Rezdiffra, eyeing strong growth despite competition risks. - Pluang
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits - Quiver Quantitative
Insider Sell: David Soergel Sells Shares of Madrigal Pharmaceuti - GuruFocus
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares - Investing.com
Madrigal (MDGL) CMO sells 1,042 shares in 10b5-1 trade, holds 10,033 - Stock Titan
MDGL (NASDAQ) insider files Form 144 reporting sale of 1,042 shares - Stock Titan
Citizens reiterates Madrigal Pharmaceuticals stock rating on liver data By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 35.71% Potential Upside - DirectorsTalk Interviews
Has Madrigal Pharmaceuticals (MDGL) Cracked the Code for MASH - Kavout
H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620 - Moomoo
Madrigal Expands Workforce With Equity Hiring Grants - MyChesCo
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rez - GuruFocus
Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients - Moomoo
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rezdiffra for MASH Treatment - GuruFocus
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH - The Manila Times
Madrigal Presents Data Demonstrating Rezdiffra Reduced - GlobeNewswire
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,928,716, According to a Recent SEC Filing - Moomoo
(MDGL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 30% Upside Beckons in the Biotech Sector - DirectorsTalk Interviews
MDGL Stock Price Prediction 2025-2026 | Madrigal Pharmaceuticals Inc Forecast - 24/7 Wall St.
Insider Sell: Richard Levy Sells Shares of Madrigal Pharmaceuticals Inc (MDGL) - GuruFocus
Director Richard Levy of Madrigal (MDGL) sells 5,682 shares under plan - Stock Titan
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):